Proteasome Inhibition Measurements: Clinical Application
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. An accurate pharmacodynamic assay has been developed as an alternative or complement to pharmacokinetic measurements. Methods: Fluorogenic kinetic assays for both the chymotryptic and tryptic activities of the proteasome have been optimized for both whole blood and blood cells. Using the ratio of these activities and the catalytic mechanism of the proteasome, we developed a novel method of calculating percentage of inhibition, using two structurally unrelated inhibitors (PS-341 and lactacystin). Results: This ratio method was demonstrated to be sensitive (detection limit of 13% inhibition with 10 μg of cell lysate), specific to the proteasome (PS-341 provides >98% inhibition), accurate (112% analyte recovery), and precise (0% ± 5% inhibition at 0 nmol/L PS-341 and 74.5% ± 1.7% inhibition at 200 nmol/L PS-341). Using these assays, we found that both erythrocytes and leukocytes contain proteasome at 3 μmol/L. Pharmacodynamic results for PS-341 obtained from the whole-blood ratio method were comparable to those using leukocytes determined by another method. Conclusions: The described assay provides a reliable method for studying the pharmacodynamics of proteasome inhibitors and is now in use in concurrent phase I clinical trials with PS-341.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,614
Self-citationThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685 · cited 2×
“Inhibitors of the proteasome have been designed based on either the natural product, lactacystin (9 ), or synthetic peptidyl derivatives (10 ). PS-341, a peptidyl boronic acid, is a novel inhibitor of the chymotryptic site within the 20S proteasome ( 11 ). This molecule shows at least 500-fold selectivity for the prot…”
BackgroundInfluentialSelf-citationThe Proteasome, a Novel Protease Regulated by Multiple Mechanisms
DeMartino, G. N., & Slaughter, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22123 · Cited by 530
Lactacystin, Proteasome Function, and Cell Fate
Fenteany, G., & Schreiber, S. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8545 · Cited by 410
Tanaka, K., Ii, K., Ichihara, A., Waxman, L., & Goldberg, A. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66853-x · Cited by 324
Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15671 · Cited by 287
Self-citationUbiquitin and the Biology of the Cell
(1998) · Springer eBooks · doi:10.1007/978-1-4899-1922-9 · Cited by 271
Subcellular Localization, Stoichiometry, and Protein Levels of 26 S Proteasome Subunits in Yeast
Russell, S. J., Steger, K. A., & Johnston, S. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21943 · Cited by 194
Cited by
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Self-citationEvaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Groll, M., Berkers, C. R., Ploegh, H. L., & Ovaa, H. (2006) · Structure · doi:10.1016/j.str.2005.11.019 · Cited by 473
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434
Self-citation20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development
Borissenko, L., & Groll, M. (2007) · Chemical Reviews · doi:10.1021/cr0502504 · Cited by 407
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
Self-citationMonitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates
Kisselev, A. F., & Goldberg, A. L. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)98030-0 · Cited by 346
Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma
Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., Bradley, S., Gobburu, J. V., Goheer, A., Lee, S.-L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0781 · Cited by 343
Adsule, S., Barve, V., Chen, D., Ahmed, F., Dou, Q. P., Padhye, S., & Sarkar, F. H. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060712l · Cited by 334
Perry, D. K., Burns, J. M., Pollinger, H. S., Amiot, B. P., Gloor, J. M., Gores, G. J., & Stegall, M. D. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02461.x · Cited by 329
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Self-citationChauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., & Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0476 · Cited by 316
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Dick, L. R., & Fleming, P. E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.008 · Cited by 273
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., & Galardy, P. J. (2005) · Nature Methods · doi:10.1038/nmeth759 · Cited by 262
Why do cellular proteins linked to K63‐polyubiquitin chains not associate with proteasomes?
Nathan, J. A., Tae Kim, H., Ting, L., Gygi, S. P., & Goldberg, A. L. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.354 · Cited by 253
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401563101 · Cited by 244
Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach
Groll, M., & Huber, R. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.025 · Cited by 193
“Structural and functional information on proteasomal inhibitors allowed the Millennium Pharmaceuticals company to develop a proteasome inhibitor named Valcade (bortezomib), which passed in 2004 clinical phase III study, and now represents a newly approved prescription drug against multiple myeloma [63–65].”
BackgroundImaging 26S proteasome activity and inhibition in living mice
Luker, G. D., Pica, C. M., Song, J., Luker, K. E., & Piwnica-Worms, D. (2003) · Nature Medicine · doi:10.1038/nm894 · Cited by 174
“In animal models and patients, proteasome activity is typically measured in blood samples with an assay of the isolated 20S core particle rather than the intact 26S proteasom”
BackgroundAscorbic acid inhibits antitumor activity of bortezomib in vivo
Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia · doi:10.1038/leu.2009.83 · Cited by 109
Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104
Profiling proteasome activity in tissue with fluorescent probes
Berkers, C. R., van Leeuwen, F. W. B., Groothuis, T. A., Peperzak, V., van Tilburg, E. W., Borst, J., Neefjes, J. J., & Ovaa, H. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700256 · Cited by 102
Huang, J., Campian, J. L., Gujar, A. D., Tran, D. D., Lockhart, A. C., DeWees, T. A., Tsien, C. I., & Kim, A. H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2104-2 · Cited by 79
Huang, J., Campian, J. L., Gujar, A. D., Tsien, C., Ansstas, G., Tran, D. D., DeWees, T. A., Lockhart, A. C., & Kim, A. H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2775-y · Cited by 52
“Pharmacodynamic studies on chymotrypsin-like 20S proteasome activities were performed with fluorometric 20S proteasome assay as previously described using fluorogenic substrate Suc-LLVY-AMC and lysate of peripheral whole blood or white blood cells (WBCs) taken at baseline, after 2 weeks, and after 4 weeks of DSF [14].”
Method
Metadata
- Authors
- Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-05-01
- Volume
- 46
- Issue
- 5
- Pages
- 673-683
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1935443268
- Cited by
- 301
- References
- 19
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.